This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
In a new analysis of a case-control study based on the French KIDSEP cohort, Mikaeloff et al.1 conclude that there is no overall association of hepatitis B vaccine (HB) with acute onset demyelinating disease but that there is a long-term increase in the risk of multiple sclerosis (MS) in children compliant with national vaccination schedules and immunized against HB with the Engerix B® vaccine.
Unfortunately, these results were leaked to the lay press before their publication in Neurology®, fueling new rumors about the risk of HB vaccination. We would like to stress major interpretational issues that preclude any reliable conclusion from being drawn about a possible link in this study between the Engerix R® vaccine and the risk of MS in children.
A very large number of analyses were undertaken. A total of 50 results appear in the article, and the list of “sensitivity” analyses suggests that many more were done. The probability of detecting several significant associations through pure chance was therefore very high.
Concluding that there is a difference between Engerix B® and other vaccines because the odds …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis
Recombinant hepatitis B vaccine and the risk of multiple sclerosis
Hepatitis vaccines and pediatric multiple sclerosis
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood